Revenio Group Corporation has published its Annual Report, Report by the Board of Directors and Financial Statements, Corporate Governance Statement and Remuneration Statement of 2018

Revenio Group Corporation, Stock Exchange Release, 27 February 2019 at 10.30

Revenio Group Corporation’s Annual Report, Report by the Board of Directors and Financial Statements 2018 have been published in company’s internet pages in Finnish and English at:

https://www.reveniogroup.fi/en/investors/financial-reports/ (English)

https://www.reveniogroup.fi/sijoittajille/taloudelliset-raportit/ (Finnish)

The Annual Report contains CEO’s review as well as information on Revenio’s business and operating environment. Report by the Board of Directors and Financial Statements contains also Corporate Governance Statement.

In addition, Revenio has published a separate Remuneration Statement in Finnish and English at:

https://www.reveniogroup.fi/en/investors/corporance-governance-statement (English)

https://www.reveniogroup.fi/sijoittajille/hallinto-ja-ohjausjarjestelma (Finnish)

The Annual Report, Report by the Board of Directors and Financial Statements, Corporate Governance Statement as well as the Remuneration Statement are all available as an attachment to this Stock Exchange Release. Revenio does not publish the above mentioned documents in printed formats.

REVENIO GROUP CORPORATION

For further information, please contact:

CEO and President Timo Hildén

tel. +358 40 580 4774

timo.hilden@revenio.fi

www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

www.revenio.fi

Revenio Group in brief

The Revenio Group is a globally successful Finnish health technology company. We develop and commercialize effective and easy-to-use health tech-related screening devices for the detection of diseases of significance to public health.

We are currently focusing on the detection and measurement of glaucoma, skin cancer and asthma. Our markets are global and our products are sold in more than 100 countries.

The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings in health care via preventive measures.

In 2018, the Revenio Group's net sales totaled EUR 30.7 million, with its operating margin standing at 33.3% of net sales. Revenio Group Corporation is listed on Nasdaq Helsinki.